PRTC

PureTech Health plc (NASDAQ:PRTC) is a clinical-stage biotherapeutics company founded in 2015 and headquartered in Boston, Massachusetts. The company operates through a distinctive "hub-and-spoke" model, where it develops early-stage therapeutic programs internally before spinning them out into independent "Founded Entities" that attract third-party investment. PureTech went public on NASDAQ in November 2020 and has since established itself as a unique player in the biotechnology sector, with a portfolio spanning treatments for neurological disorders, cancer, inflammatory diseases, and rare conditions.